AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Zenas BioPharma Q3 results: obexelimab trial topline results expected by year-end, secures funding agreement.
ByAinvest
Wednesday, Nov 12, 2025 7:16 am ET1min read
• Zenas BioPharma reports Q3 2025 financial results • Obexelimab Phase 3 INDIGO trial topline results in IgG4-RD expected end-2025 • Phase 2 MoonStone trial of obexelimab in RMS reported positive 12-week primary endpoint results • Secured development and commercialization rights for three autoimmune product candidates • Entered funding agreement with Royalty Pharma for up to $300M • Agreement includes $75M upfront to support clinical development and potential commercial launch
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet